KYTX — Kyverna Therapeutics Share News
0.000.00%
Last trade - 00:00- $354.36m
- $179.94m
Brief: Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial Of Miv-Cel (Kyv-101) In Stiff Person Syndrome
Kyverna's cell therapy meets main goal of mid-stage study
Brief: Kyverna Therapeutics Announces Positive Interim Phase 2 Data From KYSA-6 Study Of KYV-101 In Generalized Myasthenia Gravis At AANEM 2025
Brief: Kyverna Therapeutics Says Phase 3 Enrollment For Kysa-6 Trial To Start By Year-End
Brief: Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
Kyverna Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kyverna Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
Brief: Kyverna Therapeutics Announces Appointment Of New Chief Financial Officer
Kyverna Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results
Kyverna Therapeutics Inc expected to post a loss of $1.11 a share - Earnings Preview
Brief: Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To Time - SEC Filing
Brief: Kyverna Therapeutics Inc Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical And Regulatory Catalysts
Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Kyverna Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Kyverna Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview
Brief: Kyverna Therapeutics To Highlight Near-Term Strategic Priorities And Key Milestones At The 43Rd Annual J.P. Morgan Healthcare Conference
Brief: Unnatural Products Appoints Abbas Kazimi And Mert Aktar To Board
Brief: Kyverna Therapeutics Appoints Mert Aktar To Its Board Of Directors